As life science and medical device companies seek regulatory approval for their products, they will likely encounter difficult disclosure decisions around clinical and regulatory events. Clinical trial data and milestones can present great opportunities as well as significant challenges.
If done right, these milestones are a great way to raise visibility within the investment, clinical, and scientific communities. If done wrong, the consequences may be severe.
The checklist below outlines 10 disclosure guidelines that will allow you to control the message within the investment and medical communities, maximize shareholder value, and attract new investors and strategic partners.
